# US 2022/0033460 A1 · Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033460 A1
- Document ID: US20220033460A1
- Status: Published application
- Kind: A1
- Application number: 17/397,841
- Filed: 2021-08-09
- Published: 2022-02-03
- Earliest claimed: 2020-07-30
- Assignees: Repertoire Immune Medicines, Inc.; Repertoire Immune Medicines (Switzerland) Ltd.
- Applicants: Repertoire Immune Medicines, Inc.; Repertoire Immune Medicines (Switzerland) Ltd.
- Inventors: Daniel Pregibon; Joshua Francis; Del Leistritz-Edwards; William Dunn; Violeta Rayon Estrada; Gang Liu; Jan Kisielow; Franz-Josef Obermair
- Web page: https://patentgrep.com/patent/US20220033460A1

## CPC

- A61K 39/12: Viral antigens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/46: Viral antigens
- C07K 14/005: from viruses
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 5/0636: {T lymphocytes}
- A61K 2039/572: {cytotoxic response}
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Approaches for identifying T cell epitopes from SARS-CoV-2 are provided, along with the use of such T cell epitopes diagnostically and therapeutically. Compositions including T cell epitope vaccines and T cell epitope-display reagents are provided. Methods for identifying SARS-CoV-2 T cell epitopes, methods of identifying reactive T cells and methods of using epitopes and T cells for diagnostic purposes, such as identifying particular patient subpopulations are provided. Treatment methods, including administration of T cell epitope vaccines prophylactically and administration of activated T cells therapeutically are also provided.

## Claims

### Claim 1

An isolated peptide comprising an immunodominant SARS-CoV-2 T cell epitope comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 286, 288, 324, 326, 327, and 328, wherein the peptide is no more than 100 amino acids in length, and an optional pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The isolated peptide of claim 1, wherein the T cell epitope is a CD8+ epitope.

### Claim at position 3

3-11. (canceled)

### Claim 12 (depends on 1)

The isolated peptide of claim 1, wherein the peptide is no more than 20 amino acids in length.

### Claim 13 (depends on 1)

The isolated peptide of claim 1, wherein the amino acid sequence of the peptide consists essentially of or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 286, 288, 324, 326, 327, and 328.

### Claim 14 (depends on 1)

The isolated peptide of claim 1, wherein the peptide is presentable by a major histocompatibility complex (MHC) Class I.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The isolated peptide of claim 1, where the peptide is synthetic.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A pharmaceutical composition comprising one or more peptides of claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A pharmaceutical composition comprising one or more nucleic acids encoding one or more peptides of claim 1, and a pharmaceutically acceptable carrier or excipient.

### Claim 21 (depends on 18)

The pharmaceutical composition of claim 18, further comprising a liposome or a lipid nanoparticle, wherein the one or more peptides are disposed within the liposome or the lipid nanoparticle.

### Claim 22

(canceled)

### Claim 23 (depends on 18)

The pharmaceutical composition of claim 18, further comprising an immunogenicity enhancing adjuvant.

### Claim 24 (depends on 20)

The pharmaceutical composition of claim 20, wherein the one or more nucleic acids are synthetic.

### Claim 25 (depends on 18)

A vaccine comprising the pharmaceutical composition of claim 18, wherein the vaccine stimulates a T cell mediated immune response when administered to a subject.

### Claim 26 (depends on 25)

The vaccine of claim 25, wherein the vaccine is a priming vaccine and/or a booster vaccine.

### Claim 27 (depends on 25)

The vaccine of claim 25, wherein the vaccine is a pan-coronavirus vaccine.

### Claim 28

(canceled)

### Claim 29 (depends on 18)

A method of stimulating a T cell immune response to SARS-CoV-2 in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 18.

### Claim 30 (depends on 29)

The method of claim 29, wherein the subject expresses an MHC Class I that binds the epitope.

### Claim at position 23

31-42. (canceled)

### Claim 43 (depends on 14)

A method of presenting a T cell epitope on the surface of an APC, the method comprising contacting the APC ex vivo with the peptide of claim 14, wherein the APC expresses the MHC Class I.

### Claim 44 (depends on 14)

A method of presenting a T cell epitope on the surface of an APC, the method comprising transfecting the APC ex vivo with a nucleic acid encoding the peptide of claim 14, wherein the APC expresses the MHC Class I.

### Claim 45 (depends on 44)

The method of claim 44, wherein the nucleic acid comprises an mRNA.

### Claim 46 (depends on 1)

A composition comprising an isolated APC that expresses an MHC Class I and presents on an outer cell surface of the APC the peptide of claim 1, and an optional pharmaceutically acceptable carrier.

### Claim 47 (depends on 46)

The composition of claim 46, wherein the APC is a dendritic cell, monocyte, macrophage, B cell or an artificial APC.

### Claim 48

(canceled)

### Claim 49 (depends on 46)

A method of producing activated T cells, the method comprising contacting a population of T cells in vitro with the composition of claim 46 to permit activation of one or more T cells in the population for reactivity to a SARS-CoV-2 infected cell, wherein the T cells comprise CD8+ T cells.

### Claim at position 31

50-52. (canceled)

### Claim 53 (depends on 49)

A method of stimulating a T cell immune response to SARS-CoV-2 in a subject, the method comprising administering to the subject a composition comprising a population of activated T cells produced by the method of claim 49, wherein the subject expresses the MHC Class I.

### Claim 54 (depends on 46)

The composition of claim 46, wherein:
(a) the peptide comprises the amino acid sequence of SEQ ID NO: 328, and the MHC Class I is HLA-A*01:01;
(b) the peptide comprises the amino acid sequence of SEQ ID NO: 286, and the MHC Class I is HLA-A*02:01;
(c) the peptide comprises the amino acid sequence of SEQ ID NO: 327, and the MHC Class I is HLA-A*01:01;
(d) the peptide comprises the amino acid sequence of SEQ ID NO: 326, and the MHC Class I is HLA-B*07:02;
(e) the peptide comprises the amino acid sequence of SEQ ID NO: 324, and the MHC Class I is HLA-B*07:02; and/or
(f) the peptide comprises the amino acid sequence of SEQ ID NO: 288, and the MHC Class I is HLA-A*02:01.

### Claim at position 34

55-56. (canceled)

### Claim 57 (depends on 25)

The method of claim 25, wherein the subject is at risk of infection by SARS-CoV-2.

### Claim at position 36

58-73. (canceled)

### Claim 74 (depends on 1)

A composition comprising an isolated T cell that binds the peptide of claim 1, and an optional pharmaceutically acceptable carrier.

### Claim at position 38

75-78. (canceled)

### Claim 79 (depends on 74)

The composition of claim 74, wherein the T cell is a CD8+ T cell.

### Claim at position 40

80-89. (canceled)

### Claim 90

An engineered T cell receptor (TCR) having antigenic specificity for a SARS-CoV-2 antigen, the TCR have an alpha chain and a beta chain, wherein:
(a) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 286 presented by HLA-A*02:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_22, TCR_27, TCR_47, TCR_65, TCR_69, TCR_77, TCR_84, or TCR_107 set forth in Table 5;
(b) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 288 presented by HLA-A*02:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_5, TCR_7, TCR_14, TCR_16, TCR_20, TCR_28, TCR_33, TCR_43, TCR_45, TCR_63, TCR_70, TCR_81, TCR_86, TCR_88, TCR_90, TCR_94, TCR_98, TCR_99, TCR_102, TCR_103, TCR_106, TCR_108, TCR_113, or TCR_123 set forth in Table 5;
(c) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 324 presented by HLA-B*07:02, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_16, TCR_22, TCR_27, TCR_65, TCR_97, or TCR_107 set forth in Table 5;
(d) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 326 presented by HLA-B*07:02, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_11, TCR_112, or TCR_122, set forth in Table 5;
(e) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 327 presented by HLA-A*01:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_26, TCR_53, or TCR_54 set forth in Table 5; or
(f) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 328 presented by HLA-A*01:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_25 or TCR_41 set forth in Table 5.

### Claim at position 42

91-101. (canceled)

### Claim 102

A pharmaceutical composition comprising an engineered T cell and a pharmaceutically acceptable carrier, wherein the engineered T cell comprises one or more exogenous nucleic acid sequences that encode a TCR having antigenic specificity for a SARS-CoV-2 antigen, the TCR have an alpha chain and a beta chain, wherein:
(a) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 286 presented by HLA-A*02:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_22, TCR_27, TCR_47, TCR_65, TCR_69, TCR_77, TCR_84, or TCR_107 set forth in Table 5;
(b) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 288 presented by HLA-A*02:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_5, TCR_7, TCR_14, TCR_16, TCR_20, TCR_28, TCR_33, TCR_43, TCR_45, TCR_63, TCR_70, TCR_81, TCR_86, TCR_88, TCR_90, TCR_94, TCR_98, TCR_99, TCR_102, TCR_103, TCR_106, TCR_108, TCR_113, or TCR_123 set forth in Table 5;
(c) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 324 presented by HLA-B*07:02, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_16, TCR_22, TCR_27, TCR_65, TCR_97, or TCR_107 set forth in Table 5;
(d) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 326 presented by HLA-B*07:02, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_11, TCR_112, or TCR_122, set forth in Table 5;
(e) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 327 presented by HLA-A*01:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_26, TCR_53, or TCR_54 set forth in Table 5; or
(f) the SARS-CoV-2 antigen comprises a T cell epitope comprising the amino acid sequence of SEQ ID NO: 328 presented by HLA-A*01:01, and the TCR comprises the CDR3 alpha and CDR3 beta sequences of TCR_25 or TCR_41 set forth in Table 5.

### Claim at position 44

103-107. (canceled)

### Claim 108 (depends on 102)

A method of ameliorating a symptom of SARS-CoV-2 infection in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 102, thereby to ameliorate the symptom.

### Claim at position 46

109-128. (canceled)
